Status:
COMPLETED
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
Lead Sponsor:
Veterans Medical Research Foundation
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Pfizer
Conditions:
Schizophrenia
Metabolic Syndrome X
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat stor...
Detailed Description
People with schizophrenia often lead more sedentary lifestyles than people without the disease, and they are frequently treated with antipsychotic medications that cause weight gain. Combined, these f...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia or schizoaffective disorder
- Currently receiving antipsychotic therapy with risperidone or olanzapine
- Overweight
Exclusion
- Diagnosis of diabetes
- Hospitalization for schizophrenia or schizoaffective disorder within 90 days prior to study entry
- Refractory schizophrenia or schizoaffective disorder
- Currently receiving therapy with clozapine
- No stable residence and phone number for 90 days prior to study entry
- Prior unsuccessful treatment with ziprasidone
- Intolerance to ziprasidone
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT00338949
Start Date
June 1 2006
End Date
December 1 2009
Last Update
October 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA San Diego Healthcare System
San Diego, California, United States, 92161